gemfibrozil has been researched along with Kidney Failure, Chronic in 14 studies
Kidney Failure, Chronic: The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This was a post hoc subgroup analysis in the Veterans Affairs High-Density Lipoprotein Intervention Trial, a randomized double-blind trial of gemfibrozil versus placebo in 2,531 men with coronary disease, HDL-C levels of 40 mg/dL or less (< or =1." | 9.11 | Effect of gemfibrozil on change in renal function in men with moderate chronic renal insufficiency and coronary disease. ( Bloomfield, H; Collins, D; Curhan, GC; Robins, S; Tonelli, M, 2004) |
| "To present a case of gemfibrozil-induced myositis which precipitated an acute compartment syndrome." | 7.68 | Acute compartment syndrome: an unusual presentation of gemfibrozil induced myositis. ( Chow, LT; Chow, WH, 1993) |
| "Severe rhabdomyolysis complicated by respiratory and renal failure developed three weeks after initiation of low dose lovastatin therapy in a 79 year old, non-immunocompromised patient." | 7.68 | Lovastatin-induced acute rhabdomyolysis. ( Kogan, AD; Orenstein, S, 1990) |
| "A 49-year-old woman with chronic renal failure was given gemfibrozil for hyperlipidemia." | 5.29 | Gemfibrozil induced myositis: a case report with light microscopic and ultrastructural study. ( Chow, LT; Chow, WH, 1994) |
| "This was a post hoc subgroup analysis in the Veterans Affairs High-Density Lipoprotein Intervention Trial, a randomized double-blind trial of gemfibrozil versus placebo in 2,531 men with coronary disease, HDL-C levels of 40 mg/dL or less (< or =1." | 5.11 | Effect of gemfibrozil on change in renal function in men with moderate chronic renal insufficiency and coronary disease. ( Bloomfield, H; Collins, D; Curhan, GC; Robins, S; Tonelli, M, 2004) |
| "To present a case of gemfibrozil-induced myositis which precipitated an acute compartment syndrome." | 3.68 | Acute compartment syndrome: an unusual presentation of gemfibrozil induced myositis. ( Chow, LT; Chow, WH, 1993) |
| " In 55 patients (20 on HD, 13 on CAPD and 22 NDCRF) with severe hypertriglyceridemia or diminished HDL cholesterol gemfibrozil 300 mg b." | 3.68 | Lipid abnormalities in chronic uremic patients. Response to treatment with gemfibrozil. ( Dardamanis, MA; Elisaf, MS; Papagalanis, ND; Siamopoulos, KC, 1993) |
| "Severe rhabdomyolysis complicated by respiratory and renal failure developed three weeks after initiation of low dose lovastatin therapy in a 79 year old, non-immunocompromised patient." | 3.68 | Lovastatin-induced acute rhabdomyolysis. ( Kogan, AD; Orenstein, S, 1990) |
| "Gemfibrozil treatment significantly reduces both plasma lipids and apoB, apoC-III and apoE concentrations in patients with moderately advanced renal insufficiency." | 2.68 | Effect of gemfibrozil on lipoprotein abnormalities in chronic renal insufficiency: a controlled study in human chronic renal disease. ( Alaupovic, P; Attman, PO; Knight-Gibson, C; Kron, B; Larsson, R; Mulec, H; Samuelsson, O; Weiss, L, 1997) |
| "Eighteen patients with chronic renal failure (serum creatinine 173-756 mumol/l) and hyperlipidemia were treated with gemfibrozil (1200 mg/day)." | 2.66 | Normalization of lipoprotein lipase and hepatic lipase by gemfibrozil results in correction of lipoprotein abnormalities in chronic renal failure. ( Korte, T; Kuusi, T; Pasternack, A; Solakivi, T; Vänttinen, T, 1987) |
| "Hyperlipidemia is a well-recognized complication of renal transplantation." | 2.38 | Hyperlipidemia and transplantation: etiologic factors and therapy. ( Belzer, FO; D'Alessandro, AM; Kalayoglu, M; Knechtle, SJ; Pirsch, JD; Reed, A; Sollinger, HW, 1992) |
| "A 49-year-old woman with chronic renal failure was given gemfibrozil for hyperlipidemia." | 1.29 | Gemfibrozil induced myositis: a case report with light microscopic and ultrastructural study. ( Chow, LT; Chow, WH, 1994) |
| "A 61-year-old woman with hyperlipidemia was treated with gemfibrozil." | 1.29 | [Gemfibrozil-induced myopathy]. ( Adler, Y; Aron, A; Weiss, P, 1993) |
| "Patients with chronic renal failure appear at greater risk for skeletal muscle side effects from the fibric acid group of lipid lowering agents." | 1.29 | Skeletal muscle metabolism before and after gemfibrozil treatment in dialysed patients with chronic renal failure. ( Irish, A; Kemp, GJ; Radda, GK; Taylor, DJ; Thompson, CH, 1996) |
| "Gemfibrozil was determined in plasma and urine by means of a HPLC method." | 1.28 | Gemfibrozil absorption and elimination in kidney and liver disease. ( Knauf, H; Kölle, EU; Mutschler, E, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.14) | 18.7374 |
| 1990's | 10 (71.43) | 18.2507 |
| 2000's | 3 (21.43) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tonelli, M | 2 |
| Collins, D | 2 |
| Robins, S | 2 |
| Bloomfield, H | 2 |
| Curhan, GC | 2 |
| Dogra, G | 1 |
| Irish, A | 2 |
| Chan, D | 1 |
| Watts, G | 1 |
| Chow, LT | 2 |
| Chow, WH | 2 |
| Aron, A | 1 |
| Adler, Y | 1 |
| Weiss, P | 1 |
| Elisaf, MS | 1 |
| Dardamanis, MA | 1 |
| Papagalanis, ND | 1 |
| Siamopoulos, KC | 1 |
| Thompson, CH | 1 |
| Kemp, GJ | 1 |
| Taylor, DJ | 1 |
| Radda, GK | 1 |
| Akçiçek, F | 1 |
| Ok, E | 1 |
| Duman, S | 1 |
| Kürsad, S | 1 |
| Unsal, A | 1 |
| Alev, M | 1 |
| Atabay, G | 1 |
| Basçi, A | 1 |
| Samuelsson, O | 1 |
| Attman, PO | 1 |
| Knight-Gibson, C | 1 |
| Kron, B | 1 |
| Larsson, R | 1 |
| Mulec, H | 1 |
| Weiss, L | 1 |
| Alaupovic, P | 1 |
| Pirsch, JD | 1 |
| D'Alessandro, AM | 1 |
| Sollinger, HW | 1 |
| Knechtle, SJ | 1 |
| Reed, A | 1 |
| Kalayoglu, M | 1 |
| Belzer, FO | 1 |
| Knauf, H | 1 |
| Kölle, EU | 1 |
| Mutschler, E | 1 |
| Kogan, AD | 1 |
| Orenstein, S | 1 |
| Pasternack, A | 1 |
| Vänttinen, T | 1 |
| Solakivi, T | 1 |
| Kuusi, T | 1 |
| Korte, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase IV, Single Center Pilot Study Using Alemtuzumab (Campath-1H) Induction Combined With Prednisone-Free, Calcineurin-Inhibitor-Free Immunosuppression in Kidney Transplantation[NCT00166712] | Phase 4 | 40 participants (Actual) | Interventional | 2005-04-30 | Terminated (stopped due to Study stopped due to lack of efficacy & funding.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The incidence of rejection is determined by the proportion of patients experiencing biopsy proven acute allograft rejection during the first 12 months post-transplant. (NCT00166712)
Timeframe: Within 12 months post kidney transplant
| Intervention | Participants (Number) |
|---|---|
| Groups | 4 |
| Group 2 | 6 |
1 review available for gemfibrozil and Kidney Failure, Chronic
| Article | Year |
|---|---|
Hyperlipidemia and transplantation: etiologic factors and therapy.
Topics: Adrenal Cortex Hormones; Antihypertensive Agents; Coronary Disease; Diuretics; Gemfibrozil; Humans; | 1992 |
6 trials available for gemfibrozil and Kidney Failure, Chronic
| Article | Year |
|---|---|
Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficiency.
Topics: Aged; Cardiovascular Diseases; Creatinine; Gemfibrozil; Humans; Hypolipidemic Agents; Incidence; Kid | 2004 |
Effect of gemfibrozil on change in renal function in men with moderate chronic renal insufficiency and coronary disease.
Topics: Aged; Cholesterol, HDL; Confounding Factors, Epidemiologic; Coronary Disease; Double-Blind Method; F | 2004 |
A randomized trial of the effect of statin and fibrate therapy on arterial function in CKD.
Topics: Adult; Aged; Atorvastatin; Brachial Artery; Double-Blind Method; Elasticity; Endothelium, Vascular; | 2007 |
Lipid-lowering effects of simvastatin and gemfibrozil in CAPD patients: a prospective cross-over study.
Topics: Adult; Aged; Cholesterol; Combined Modality Therapy; Cross-Over Studies; Diet, Fat-Restricted; Femal | 1996 |
Effect of gemfibrozil on lipoprotein abnormalities in chronic renal insufficiency: a controlled study in human chronic renal disease.
Topics: Apolipoproteins; Cholesterol; Female; Gemfibrozil; Glomerular Filtration Rate; Humans; Hypolipidemic | 1997 |
Normalization of lipoprotein lipase and hepatic lipase by gemfibrozil results in correction of lipoprotein abnormalities in chronic renal failure.
Topics: Adult; Aged; Clinical Trials as Topic; Enzyme Activation; Female; Gemfibrozil; Humans; Kidney Failur | 1987 |
7 other studies available for gemfibrozil and Kidney Failure, Chronic
| Article | Year |
|---|---|
Gemfibrozil induced myositis: a case report with light microscopic and ultrastructural study.
Topics: Biopsy; Female; Gemfibrozil; Humans; Kidney Failure, Chronic; Middle Aged; Mitochondria, Muscle; Mus | 1994 |
[Gemfibrozil-induced myopathy].
Topics: Diabetes Complications; Female; Gemfibrozil; Humans; Hyperlipidemias; Kidney Failure, Chronic; Middl | 1993 |
Acute compartment syndrome: an unusual presentation of gemfibrozil induced myositis.
Topics: Acute Disease; Biopsy; Compartment Syndromes; Female; Gemfibrozil; Humans; Hyperlipidemias; Kidney F | 1993 |
Lipid abnormalities in chronic uremic patients. Response to treatment with gemfibrozil.
Topics: Adult; Aged; Cholesterol, HDL; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hyperlipidemias; H | 1993 |
Skeletal muscle metabolism before and after gemfibrozil treatment in dialysed patients with chronic renal failure.
Topics: Adult; Aged; Cholesterol; Exercise; Female; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agen | 1996 |
Gemfibrozil absorption and elimination in kidney and liver disease.
Topics: Adult; Aged; Chromatography, High Pressure Liquid; Female; Gemfibrozil; Half-Life; Humans; Intestina | 1990 |
Lovastatin-induced acute rhabdomyolysis.
Topics: Acute Disease; Age Factors; Aged; Drug Therapy, Combination; Female; Gemfibrozil; Humans; Kidney Fai | 1990 |